Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma
- 15 December 2004
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (24), 4881-4887
- https://doi.org/10.1200/jco.2004.12.126
Abstract
Purpose: To evaluate the feasibility of and response rate to an intensified induction chemotherapy regimen for young children with newly diagnosed high-risk or disseminated medulloblastomas. Patients and Methods: From January 1997 to March 2003, 21 patients with high-risk or disseminated medulloblastoma were enrolled. After maximal surgical resection, patients were treated with five cycles of vincristine (0.05 mg/kg/wk × three doses per cycle for three cycles), cisplatin (3.5 mg/kg per cycle), etoposide (4 mg/kg/d × 2 days per cycle), cyclophosphamide (65 mg/kg/d × 2 days per cycle) with mesna, and methotrexate (400 mg/kg per cycle) with leucovorin rescue. Following induction chemotherapy, eligible patients underwent a single myeloablative chemotherapy cycle with autologous stem-cell rescue. Results: Significant toxicities of this intensified regimen, including gastrointestinal and infectious toxicities, are described. Among the 21 patients enrolled, there were 17 complete responses (81%), two partial responses, one stable disease, and one progressive disease. The 3-year event-free survival and overall survival are 49% (95% CI, 27% to 72%) and 60% (95% CI, 36% to 84%), respectively. Conclusion: This intensified induction chemotherapy regimen is feasible and tolerable. With the majority of patients with disseminated medulloblastoma having M2 or M3 disease at diagnosis, the encouraging high response rate of this intensified induction regimen suggests that such an addition of methotrexate should be explored in future studies.Keywords
This publication has 24 references indexed in Scilit:
- Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER updateMedical and Pediatric Oncology, 2002
- Activity of postoperative carboplatin, etoposide, and high‐dose methotrexate in pediatric CNS embryonal tumors: Results of a phase II study in newly diagnosed childrenMedical and Pediatric Oncology, 2002
- Improved Survival of Children with Advanced Neuroblastoma Treated by Intensified Therapy Including Myeloablative Chemotherapy with Stem Cell Transplantation: A Retrospective Analysis from the Tohoku Neuroblastoma Study GroupThe Tohoku Journal of Experimental Medicine, 2001
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- The treatment of malignant brain tumors in infants and very young children: An update of the Pediatric Oncology Group experienceNeuro-Oncology, 1999
- Postoperative Chemotherapy in Children Less Than 4 Years of Age with Malignant Brain TumorsJournal of Pediatric Hematology/Oncology, 1998
- An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children.Archives of Disease in Childhood, 1996
- Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?Journal of Neuro-Oncology, 1996
- Postoperative Chemotherapy and Delayed Radiation in Children Less Than Three Years of Age with Malignant Brain TumorsNew England Journal of Medicine, 1993
- Methotrexate Concentration Levels in the Cerebrospinal Fluid During High-Dose Methotrexate Infusions: An Unreliable PredictionPediatric Hematology and Oncology, 1988